PharmD | MSc in Clinical Microbiology and Infectious Diseases | Research Assistant (Institut Micalis, INRAE, BaPS)
Antibody–drug conjugates (ADCs) have emerged as a promising class of cancer therapeutics -- After revolutionizing the treatment of HER2+ and TNBC MBC finally the ADCs joined the treatment arsenal of HR+ mBC -- T-DXd is approved in metastatic hormone refractory HR+/HER2 low mBC that had previously received at least one line of chemotherapy in metastatic setting -- SG is approved in any hormone refractory HR+/ HER2- mBC that had received at least 2 lines of systematic therapy -- We desperately need to identify biomarkers to predict their efficacy and inform the treatment sequencing
Congratulations IVPN-Network, FZ, LLE Nabih Sleiman Ahlam Alhadi Munquith Mohammed
Passionate Student Leader | IVPN-Network | LIU-IVPN Student Club
4moCongrats dear 👍